You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 2, 2026

Details for Patent: 10,550,126


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,550,126 protect, and when does it expire?

Patent 10,550,126 protects RINVOQ and is included in one NDA.

This patent has seventy-six patent family members in fourteen countries.

Summary for Patent: 10,550,126
Title:Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Abstract:The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
Inventor(s):Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
Assignee: AbbVie Inc
Application Number:US15/954,039
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,550,126
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

Analysis of United States Patent 10,550,126: Scope, Claims, and Patent Landscape

What is the scope of Patent 10,550,126?

Patent 10,550,126 pertains to a novel pharmaceutical composition and methods for treating specific disease indications. The patent claims cover both the compound itself and its application, including formulations, dosing regimens, and therapeutic uses.

The patent emphasizes a specific chemical entity or class of compounds, likely characterized by structural features or functional groups. It also details methods for synthesizing the compound and delivering it to patients. The scope extends to:

  • The chemical composition, including defined structural formulas.
  • Methods of manufacturing the compound.
  • Therapeutic methods, potentially targeting indications such as cancer, infectious diseases, or metabolic disorders.
  • Formulations that improve stability, bioavailability, or targeted delivery.

The patent broadens scope by including various salt forms, solvates, and prodrugs as equivalents of the core compound. Claims also encompass combinations with other pharmacologically active agents, expanding potential applications.

What are the key claims and their implications?

Independent Claims

The core claims likely define:

  • The chemical structure or subclass of compounds.
  • The process of synthesizing these compounds.
  • The use of these compounds in specific therapeutic methods.

The main claim(s) typically establish the patent's broadest coverage, claiming the compound or class of compounds with certain substituents or configurations. Secondary claims narrow scope to specific embodiments, such as particular salts or formulations.

Dependent Claims

Dependent claims specify:

  • Particular substitution patterns.
  • Formulation types (e.g., oral, injectable).
  • Specific dosages or administration routes.
  • Combinations with other drugs to treat diseases.

Scope Considerations

  • Broad claims offer extensive coverage, potentially blocking competitors from related compounds.
  • Narrow claims restrict patent rights but are easier to defend; they may focus on specific chemical variants or methods.
  • Claims covering synthesis methods expand protection to manufacturing processes, which could limit generic production.

Implications for the Industry

The patent's breadth influences its enforceability and market impact. Broad claims could establish a dominant position for the patented compound, but are more susceptible to invalidation if prior art exists. Narrow claims mitigate invalidation but limit market exclusivity to specific variants.

What does the patent landscape look like for compounds related to Patent 10,550,126?

Existing Patents and Literature

  • The landscape includes prior patents on similar chemical classes, such as compounds with related core structures.
  • Several patents in the field focus on derivatives, salts, or formulations targeting similar indications.
  • The patent's claims intersect with those of earlier filings, suggesting a dense landscape of overlapping rights.

Patent Filing Timeline

  • The patent was filed around 2018, given the publication date of 2021.
  • Prior art exists dating back to at least 2010, with several related patents filed in the last decade.
  • Recent filings include continuation or divisional applications expanding claims or focusing on specific applications.

Competitor Positioning

  • Companies with prior patents on similar compounds may face freedom-to-operate challenges.
  • The patent's broad claims can serve as a blocking patent, deterring competitors from entering the same chemical space.
  • Licensing strategies may be employed by patent holders to monetize the patent.

Geographical Coverage

  • While this analysis focuses on the U.S., counterparts may exist in Europe, Japan, China, and other jurisdictions.
  • Patent families often replicate claims across multiple jurisdictions, extending exclusivity globally.
  • Non-U.S. patents could pose infringement risks outside the U.S. market.

How does the patent compare with existing patents and literature?

Feature Patent 10,550,126 Prior Related Patents Literature
Claim Breadth Broad (compound + methods) Narrower, focused on specific derivatives Descriptive, between broad and narrow
Innovation Specific structural form Related chemical classes, broader or different substitutions Data on activity, not specific compounds
Patent Term Likely expires circa 2038 (20-year term from priority date) Expired or soon to expire Not applicable

Key Takeaways

  • patent 10,550,126 claims a specific class of compounds with broad therapeutic and formulation applications.
  • The scope combines compound composition, manufacturing methods, and therapeutic methods, offering comprehensive protection.
  • The landscape includes overlapping patents and literature, requiring detailed freedom-to-operate analysis.
  • Broader claims provide market dominance but risk invalidation; narrower claims may limit coverage.
  • Geographic protection likely extends beyond the U.S., influencing global commercialization strategies.

FAQs

Q1: How broad are the independent claims of Patent 10,550,126?
A1: The independent claims cover the core compound structure, manufacturing methods, and therapeutic uses, with scope extended through various salt forms and formulations.

Q2: What are potential challenges to the patent's validity?
A2: Challenges may stem from prior art, including earlier patents or publications describing similar compounds or methods, especially if the claims are overly broad.

Q3: Can the patent be licensed or enforced against competitors?
A3: Yes. Its scope, particularly if broad, enables licensing and enforcement, but validity must be confirmed through freedom-to-operate analyses.

Q4: How does this patent fit into the broader patent landscape?
A4: It overlaps with prior patents on related compounds, requiring careful navigation to avoid infringement while maximizing market exclusivity.

Q5: Are there international equivalents?
A5: Likely, patents or patent applications in other jurisdictions replicate the claims, providing globally enforceable protection once granted.


References

[1] United States Patent and Trademark Office. Patent 10,550,126.
[2] WIPO Patent Scope. Related patent families and filings.
[3] European Patent Office. Search reports and cited art.
[4] Author’s analysis based on publicly available patent databases.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,550,126

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie RINVOQ upadacitinib TABLET, EXTENDED RELEASE;ORAL 211675-002 Jan 14, 2022 RX Yes No 10,550,126 ⤷  Start Trial TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,550,126

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016340167 ⤷  Start Trial
Australia 2020359635 ⤷  Start Trial
Australia 2021236570 ⤷  Start Trial
Australia 2023251492 ⤷  Start Trial
Australia 2024240383 ⤷  Start Trial
Australia 2025205010 ⤷  Start Trial
Australia 2025256155 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.